Sutaria Saumya

CEO Sutaria Saumya sold 78,762 shares at avg $190.78 on 2025-09-10 for $15.0M, reducing holdings by 17.6%.

Saumya conducted 2 separate sales totaling 78,762 shares (78.8K shares) for $15,026,139.08 ($15.0M), executed at blended average price of $190.78 per share. The sale reduces her post-transaction holdings to 368,683 shares (368.7K shares), representing a 17.6% reduction from pre-transaction holdings of 447,445 shares (447.4K shares). At the ticker-specific level, her prior 4 trades at THC show a 0% well-timed rate at the 90-day mark, with returns following those sales ranging from +4.5% to +5.7%, suggesting her past sales preceded gains rather than declines. Current market conditions show THC trading at $192.82, only -1.8% from its 52-week high of $196.39, with strong recent momentum (+12.2% over 30 days, +17.3% over 90 days), creating context for this large liquidation near recent highs.

Sutaria (CEO) sold entire 100.0K share position in 4 separate sales for $15,443,768.92 at blended $154.44, reducing holdings to 0%.

Sutaria Saumya, Chairman & CEO of Tenet Healthcare, executed 4 separate sales totaling 100,000 shares for $15,443,768.92 between August 14–15, 2024, at prices ranging from $154.35 to $155.40—near the current price of $156.66, which stands at the 52-week high. The complete liquidation reduced his holdings from 100,000 shares to 0, representing a 100% exit from his equity position. This occurs in the context of Tenet trading at a P/E of 4.25 and recently posting net income of $477.0M on $5.1B quarterly revenue, with stock appreciation of +17.4% over the past 30 days and +21.9% over 90 days. The full elimination of the CEO's equity stake—rather than a partial reduction—is a material shift in insider alignment with shareholders and merits close examination of any disclosed timing or plan mechanics, as well as forward guidance and operational developments that may inform the transaction context.